Navigation Links
GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
Date:3/8/2010

CRANBURY, N.J., March 8 /PRNewswire/ -- Replication Medical, Inc., a developer of proprietary, hydrogel based products for the spine and other surgical applications, announced today that it has received a CE mark for its GelFix Posterior Spinal Distraction implant.    A CE mark is the quality assurance certification requirement recognized by members of the European Union for sales into those countries.

The GelFix device is a one-piece posterior spinal implant made from HPAN, a biocompatible hydrogel which exhibits desirable mechanical properties including compressive resistance with a dynamic response.  The GelFix distraction implant is used as a spacer between the spinous processes to provide separation and prevent nerve pinching.  The product is available in three sizes to fit the typical range of spinal stenosis patients.

The CE mark for this implant follows the approval the company received last year from the Food and Drug Administration (FDA) to market its EnGuard™ Vessel Guard.  The EnGuard device is indicated for use as a protective cover for blood vessels following anterior spine surgery and is composed of the same biocompatible polymer.

The EnGuard Vessel Guard is the first in a series of innovative products based on their proprietary hydrogel technology that the company is launching this year in the United States.

Commenting on these developments, Ann Prewett, President and CEO, said, "The GelFix implant provides a unique, minimally invasive solution for treating spinal stenosis, a leading cause of back pain."   The GelFix device acts as a dynamic spacer, compressing under load yet maintaining separation of the interspinous space.  In this manner, some of the complications associated with rigid spacers such as breakage of the bones of the spinous process or subsidence may be avoided.    

"Our products provide a technologically advanced alternative to the conventional metal and hard plastic implants which have dominated orthopedics and spine to date.   Replication Medical looks forward to entering these markets because we offer the only technology which provides a biomimetic solution to treat these medical conditions," she explained.

The GelFix interspinous implant may not only reduce pain, but also increase the mobility of the patient.   "The key to the procedure is the minimally invasive technique which can be used to implant the device.  We insert the implant between the appropriate spinous processes and in 8-10 hours, the implant increases in size and gives us the stability that we need," said Carl Lauryssen, M.D., one of Replication Medical's surgeon advisors.

The GelFix Posterior Spinal Distraction Implant is not currently approved for sale or distribution in the United States.

ABOUT REPLICATION MEDICAL

Replication Medical, Inc. is a developer of proprietary, hydrogel based products for the spinal market and other surgical applications.   Headquartered in Cranbury, New Jersey, the Company is a leader in the design and development of novel biometic hydrogel implants.  

SOURCE Replication Medical, Inc.

Back to top
'/>"/>
SOURCE Replication Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
6. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
9. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
10. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
11. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
(Date:2/11/2016)... -- Stem cells are primitive cells found in all ... capacity to differentiate into mature cell types Stem cells ... mouse embryonic stem cells were derived from embryos in ... first culturing of embryonic stem cells from non-human primates ... 2006 As a result of these discoveries, stem cells ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... The producers of Enterprises TV are pleased to present ... world of instantaneous consumption proves very convenient for businesses. With new technologies constantly becoming ... which pollutes our air, water, and soil. It can also threaten the lives of ...
(Date:2/13/2016)... , ... February 13, 2016 , ... In the early ... They’ll groom themselves to perfection, go out of their way to be romantic, and ... just take a look at any online dating profile. , A recent study ...
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... that nominations have closed for the ISE Southeast Awards 2016. Finalists and winners ... at the ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 ...
Breaking Medicine News(10 mins):